secwatch.observer — SEC 8-K summary
======================================

Issuer:     FEMASYS INC (FEMY)
CIK:        0001339005
Form:       8-K
Filed at:   2022-01-20T23:59:59+00:00
Accession:  0001140361-22-002108
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Femasys appoints Wendy Perrow to board, replacing William Witte
---------------------------------------------------------------

- William Witte resigned from board effective Jan 19, 2022; no disagreement cited.
- Wendy Perrow elected as Class II director, to serve on Compensation Committee.
- Anne Morrisey added to Nominating and Governance Committee.
- Perrow brings biotech leadership; previously CEO of AsclepiX and Alba Therapeutics.
- Company advancing FemaSeed de novo trial and FemBloc pivotal trial in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339005/000114036122002108/0001140361-22-002108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339005/000114036122002108/brhc10032968_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-002108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer